(WELL) HAN-GINS Indxx Healthcare - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Etf • ISIN: IE000GEHNQU9 • Sector Equity Technology
WELL: Healthcare, Technology, Biotech, Pharmaceuticals
The HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF (XETRA: WELL) is a Germany-domiciled ETF designed to provide exposure to the global healthcare sector, focusing on companies driving innovation and growth in medical technology, biotechnology, and healthcare services. The fund tracks the Morningstar Global Technology TME NR USD Index, which includes a diversified portfolio of equities across developed and emerging markets. With an AUM of 422.42M EUR, this ETF reflects investor interest in the long-term structural growth trends within the healthcare industry.
From a technical perspective, WELL has shown moderate trading activity, with an average 20-day volume of 4,320 shares. The ETF is currently trading at 19.44, slightly below its short-term SMA 20 of 19.85 and SMA 50 of 19.93, while remaining above its SMA 200 of 18.80. This indicates a neutral to slightly bearish short-term outlook but a bullish long-term trend. The ATR of 0.32 suggests relatively low volatility, making it appealing for risk-averse investors seeking stable exposure to the healthcare sector.
Over the next three months, based on
Additional Sources for WELL ETF
WELL ETF Overview
Market Cap in USD | 426m |
Category | Sector Equity Technology |
IPO / Inception | 2022-09-20 |
WELL ETF Ratings
Growth Rating | 53.5 |
Fundamental | - |
Dividend Rating | 49.5 |
Rel. Strength | -3.57 |
Analysts | - |
Fair Price Momentum | 13.96 EUR |
Fair Price DCF | - |
WELL Dividends
Dividend Yield 12m | 0.45% |
Yield on Cost 5y | 0.85% |
Annual Growth 5y | 89.74% |
Payout Consistency | 100.0% |
WELL Growth Ratios
Growth Correlation 3m | -88.2% |
Growth Correlation 12m | 25.6% |
Growth Correlation 5y | 93.6% |
CAGR 5y | 23.30% |
CAGR/Max DD 5y | 0.81 |
Sharpe Ratio 12m | 1.18 |
Alpha | -12.43 |
Beta | 1.208 |
Volatility | 40.91% |
Current Volume | 6.6k |
Average Volume 20d | 2.4k |
As of April 24, 2025, the stock is trading at EUR 15.52 with a total of 6,585 shares traded.
Over the past week, the price has changed by +0.60%, over one month by -13.15%, over three months by -23.89% and over the past year by -2.45%.
Partly, yes. Based on ValueRay Analyses, HAN-GINS Indxx Healthcare (XETRA:WELL) is currently (April 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 53.53 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of WELL as of April 2025 is 13.96. This means that WELL is currently overvalued and has a potential downside of -10.05%.
HAN-GINS Indxx Healthcare has no consensus analysts rating.
According to ValueRays Forecast Model, WELL HAN-GINS Indxx Healthcare will be worth about 15.6 in April 2026. The stock is currently trading at 15.52. This means that the stock has a potential upside of +0.58%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 15.6 | 0.6% |